Literature DB >> 17405185

Willingness-to-pay for a statistical life in the times of a pandemic.

Dorte Gyrd-Hansen1, Peder Andreas Halvorsen, Ivar Sønbø Kristiansen.   

Abstract

A contingent valuation was performed based on cross-sectional web-based interviews of individuals aged 16-82 years of age presenting a scenario of influenza pandemic. The mean WTP for a course of Tamiflu was NOK 1034 (median NOK 250). Anxious individuals perceived the pandemic mortality risk to be higher than others, but also perceived the benefit of Tamiflu as greater. They also expressed a higher WTP for Tamiflu, but the implied VOSL was less than for other respondents. The results suggest that fear and anxiety distort decision making under uncertainty and decrease focus on the perceived risk reduction. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17405185     DOI: 10.1002/hec.1236

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  5 in total

1.  Valuing mortality risk in the time of COVID-19.

Authors:  James K Hammitt
Journal:  J Risk Uncertain       Date:  2020-11-11

Review 2.  How to value safety in economic evaluations in health care? A review of applications in different sectors.

Authors:  Meg Perry-Duxbury; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2019-06-06

3.  Prevalence of preventive behaviors and associated factors during early phase of the H1N1 influenza epidemic.

Authors:  Joseph T F Lau; Sian Griffiths; Kai-Chow Choi; Chunqing Lin
Journal:  Am J Infect Control       Date:  2010-06       Impact factor: 2.918

4.  The forgotten numbers: A closer look at COVID-19 non-fatal valuations.

Authors:  Thomas J Kniesner; Ryan Sullivan
Journal:  J Risk Uncertain       Date:  2020-11-04

5.  Voluntary adoption of social welfare-enhancing behavior: Mask-wearing in Spain during the COVID-19 outbreak.

Authors:  Joan Barceló; Greg Chih-Hsin Sheen
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.